Navigation Links
Photonic crystal biosensors detect protein-DNA interactions
Date:9/23/2008

thought to be responsible for the maintenance of resistance-encoding plasmids in certain infectious bacteria. The second was the human apoptosis-inducing factor (AIF), a protein that binds to chromosomal DNA in a DNA-sequence-independent manner.

The photonic crystal biosensor technology was further utilized in a screen for inhibitors of the AIF-DNA interaction, and through this screen aurin tricarboxylic acid was identified as the first in vitro inhibitor of AIF.

"Aurin tricarboxylic acid displayed about 80 percent inhibition of AIF-DNA binding," Hergenrother said. "Aurin tricarboxylic acid was the only compound to exhibit significant inhibition out of approximately 1,000 compounds screened."

While the photonic crystal biosensor was demonstrated only for protein-DNA interactions, analogous experiments with protein-RNA interactions, and protein-protein interactions are also possible, Cunningham said. "We also could grow cancer cells on the photonic crystal surface, and see how different drugs affect cell growth."


'/>"/>

Contact: James E. Kloeppel
kloeppel@uiuc.edu
217-244-1073
University of Illinois at Urbana-Champaign
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. The photonic beetle
2. Scientists demonstrate the sharpest measurement of ice crystals in clouds
3. Crystal (eye) ball: Study says visual system equipped with future seeing powers
4. New clues to how proteins dissolve and crystallize
5. Scientists find missing evolutionary link using tiny fungus crystal
6. Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth
7. Unveiling the structure of microcrystals
8. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
9. Enzyme detectives uncover new reactions, products
10. Researchers study facial structures, brain abnormalities to reveal formula for detection of autism
11. Best code for disease detection, bar none
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Delivering medicine directly into a tumor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 62407 1Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 62407 2Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 1Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 2Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 3Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 4Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 5Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 6Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 7Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 8Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 9Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 10Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 11Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 12Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 13Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 14Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 15Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 16Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 17Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 18Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 19Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 20Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 21Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 22Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 23Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 24Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 25Omnetics Announces Newest Addition to Nano Circular Family 62401 1Omnetics Announces Newest Addition to Nano Circular Family 62401 2
Other Biology Technology:The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 2The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 3The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 4The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 5The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 6The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 2The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 3The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 4The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 5Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 2Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 3Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 4Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 5Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 6Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 7Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 8Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 9Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 10